On May 14, 2021 Prescient Therapeutics (PTX) reported a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs (Press release, Prescient Therapeutics, MAY 14, 2021, View Source;utm_medium=rss&utm_campaign=prescient-therapeutics-asxptx-signs-new-research-agreement-with-peter-maccallum-cancer-centre [SID1234579984]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CAR-T is a type of cellular therapy that reprograms the immune cells of cancer patients to recognise and destroy cancerous cells.

As previously reported, PTX has an existing research agreement with Peter Mac focusing on cell therapy enhancement programs, which looks to improve the current CAR-T approaches.

This new agreement extends the relationship between the parties to include the development of the OmniCAR platform.

OmniCAR is a next-generation CAR T therapy platform that offers multiple advantages over its predecessor such as control, safety, flexibility and efficacy.

PTX is developing three OmniCAR programs, including next-generation CAR-T
therapies for acute myeloid leukaemia. Her2+ solid tumours and glioblastoma multiforme.

Under the terms of the research agreement, PTX will have access to the expertise and facilities of Peter Mac.

"We are delighted to deepen our ties with a world-class institute in Peter Mac. Prescient is committed to developing all three OmniCAR programs expediently, and to the highest standard," CEO and Managing Director Steven Yatomi-Clarke said.

"This latest research program with Peter Mac is an important part of Prescient’s development plans, which include institutional and commercial laboratories," he added.